Observational Study of Clinical Practice in Patients with Pancreatic Adenocarcinoma in Greece

Table 5

Overall and progression-free survival according to first-line chemotherapy regimen in the overall population and the group of patients diagnosed during study enrolment.

	Overall population			Diagnosed during enrolment
	Median	95% CI	value	Median	95% CI	value
OS (months)
Nab-paclitaxel-gemcitabine	14.1	10.6–17.6	0.429	12.3	8.8–15.9	0.125
FOLFIRINOX/CAPOXIRI	11.1	7.7–14.6		9.9	6.4–13.5
Gemcitabine	10.4	3.0–17.7		6.1	0–14.8
Other regimens	17.1	6.6–27.6		13.2	3.4–23.0
PFS (months)
Nab-paclitaxel-gemcitabine	7.6	6.2–9.0	0.004	6.7	6.0–7.3	0.001
FOLFIRINOX/CAPOXIRI	6.9	4.1–9.7		6.3	4.6–8.0
Gemcitabine	2.9	2.7–3.0		2.9	2.5–3.2
Other regimens	7.0	3.2–10.8		5.3	1.2–9.4

CAPOXIRI, oxaliplatin/irinotecan/capecitabine; 95% CI, 95% confidence intervals; FOLFIRINOX, oxaliplatin/irinotecan/leucovorin/5-fluorouracil; OS, overall survival; PFS, progression-free survival.